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Introduction {#sec1.1}
------------

For nearly 100 years, physicians and scientists have appreciated the unique immunological status of the brain. The notion that the CNS is completely isolated from the periphery and lacks immune responses was supported by early experiments demonstrating a diffusion barrier between the blood and the brain and later by the lack of tissue graft rejection, the latter of which was proven incorrect ([@bib10]). The presence of the blood brain barrier (BBB), which isolates the central nervous system (CNS) parenchyma from circulating immune cells and antibodies, and the lack of identifiable lymphatics originally contributed to the designation of the CNS as an immune privileged site ([@bib10], [@bib151], [@bib242]). The concept of immune privilege has been questioned ([@bib36], [@bib76]) and has evolved to incorporates the neurovascular unit (NVU), the blood-cerebrospinal fluid (CSF) barrier, and the presence of CNS lymphatics that allow leukocyte egress ([@bib7], [@bib138], [@bib237]). The detection of small numbers of leukocytes, particularly memory T cells, within newly identified lymphatics and in the CSF, is in accord with reports that low numbers of T cells in the CNS promote normal neurological function, including processes involved in cognition ([@bib123], [@bib201]). Nevertheless, the most common manifestation of neuroinfectious diseases is the recruitment of inflammatory cells which are critical to mediate local resistance to a variety of viral, bacterial, and parasitic organisms within distinct compartments of the CNS (see [Table 1](#tbl1){ref-type="table"} for a list of CNS compartments targeted by neurotropic pathogens). Multiple studies have highlighted the adverse consequences of immune exclusion and the importance of immune activity to control infections in the brain. Many of these responses are associated with alterations in the biology of resident neural cell populations which not only amplify protective activities but can also impact on neuronal survival and function and lead to life-threatening pathology ([@bib212]). The aim of this article is to consider the host-pathogen interactions that influence neurotropic infections and to review advances in understanding the innate and adaptive mechanisms that balance protective and pathological inflammation, which determine the outcome of CNS infection.Table 1CNS Compartments Targeted by Neurotropic PathogensCNS CompartmentMeningesVentricular SystemParenchyma**Bacteria***S. pneumococcus*\
*L. monocytogenes*\
*H. influenza*\
*N. meningitides*\
*T. pallidumM. tuberculosisL. monocytogenes*\
*Nocardia species*\
*T. pallidum***Fungi***C. neoformansCandida albicans*\
*Aspergillus niger*\
Zygomycetes\
Fusarium species\
*Pseudallescheria boydii*\
Pigmented molds\
*Histoplasma capsulatum*\
*Coccidioides immitis*\
*Penicillium marneffei***Parasites***Angiostrongylus cantonensis*\
*Trichinella spiralisTrypanosoma brucei (sp)*\
*Schistosome(sp)T. gondii*\
*Naegleria fowleri*\
*Trypanosoma cruzi*\
*Trypanosoma brucei (sp)*\
*Taenia solium***Viruses**Enteroviruses\
West Nile virus\
Japanese encephalitis virus\
Human Immunodeficiency virus\
Mumps virus\
Measles virusJC virusHerpes simplex virus 1\
Cytomegalovirus\
Measles virus\
West Nile virus\
Japanese encephalitis virus\
Zika virus\
Tick-borne encephalitis virus\
Equine encephalitis viruses (VEEV, EEEV, WEEV)\
Enteroviruses\
Human Immunodeficiency virus\
Varicella Zoster virus\
JC virus\
Influenza A[^1]

Primary and Acquired Immune Deficiencies Associated with Susceptibility to CNS Infection {#sec1.2}
----------------------------------------------------------------------------------------

There are numerous clinical approaches such as chemotherapies, bone marrow transplantation, or immunosuppressive drugs that interfere with overall immune function and predispose to neuroinfectious diseases ([@bib29]). The AIDS epidemic revealed that T cells protect the brain from neurotropic opportunistic pathogens such as *Cryptococcus neoformans*, *Toxoplasma gondii*, *Mycobacterium tuberculosis*, cytomegalovirus (CMV), and John Cunnigham (JC) virus ([@bib26]). Similarly, children with hyper-immunoglobulin M (IgM) syndrome, a group of primary immune deficiency disorders characterized by altered CD40 signaling that results in defects in cell mediated immunity and reduced antibody class switching, exhibit increased susceptibility to encephalitis due to enteric cytopathic human orphan (ECHO) virus, CMV, and *T. gondii* ([@bib214], [@bib243]). The recent advances in whole-genome sequencing technology have intensified the investigation into the prevalence and causes of neuroinfectious diseases in patients with primary immunodeficiencies ([@bib118]). In pediatric patients with herpes simplex virus (HSV) encephalitis, these approaches have led to the identification of loss of function mutations in multiple innate immune genes including Unc-93 homolog B1 (UNC93B), Toll-like receptor (TLR)3, TIR-domain-containing adaptor-inducing interferon-β (TRIF), TNF receptor-associated factor (TRAF)3, signal transducer and activator of transcription (STAT)1, NF-κB essential modulator (NEMO), and TRAF family member-associated (TANK)-binding kinase 1 (TBK1), ([@bib37], [@bib88], [@bib95], [@bib179], [@bib195], [@bib252]). Advances in the use of human induced pluripotent stem cells (IPSC) to generate different neural cell types means that these populations can be used alone or within three-dimensional models of CNS function and combined with gene editing to dissect the basis for susceptibility. This approach has already been utilized to examine the contribution of TLR3-mediated mechanisms of resistance to HSV in different neuronal populations ([@bib130]).

The increased use of biologically based therapies to target inflammatory processes has led to the emergence of a new cohort of patients susceptible to many of the infections described above. An important example is the reactivation of the ubiquitous JC virus, which leads to a potentially fatal CNS infection that causes progressive multifocal leukoencephalopathy (PML) ([@bib17]). This pathogen has continued to rise in prominence with the advent of the humanized monoclonal antibody therapies natalizumab (anti-α4integrin) ([@bib17]) and rituximab (anti-CD20) ([@bib112]), to treat multiple sclerosis, B cell malignancies, and encephalitis due to autoantibodies against the N-methyl-D-aspartate (NMDA) receptor. The use of another anti-integrin antibody, efalizumab (anti-αLintegrin), to treat psoriasis, is also associated with increased incidence of PML ([@bib156]) and has been withdrawn from the market. The broad impact of this type of intervention is illustrated in studies in which blockade of α4 integrin compromises protective immunity in the CNS to *T. gondii*, simian immunodeficiency virus (SIV), and Bornavirus ([@bib184], [@bib197], [@bib241]). There is considerable clinical experience with anti-tumor necrosis factor (TNF) therapies to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn's disease. These therapies can also lead to infections with pathogens that exhibit tropism for the CNS that include *Listeria monocytogenes*, *Nocardia species*, *Histoplasma capsulatum*, *T. gondii*, *Cryptococcus neoformans*, *Mycobacterium tuberculosis*, and CMV ([@bib2]). These clinical examples illustrate that treatments which negatively impact immune surveillance and effector function can lead to severe infections of the CNS. Moreover, when combined with the experiences with patients with acquired immune deficiencies, they suggest that immune surveillance of the CNS occurs in the absence of overt inflammation and protects from the consequences of reactivation of persistent infections.

The Consequences of Microbial Neurotropism {#sec1.3}
------------------------------------------

For many of the micro-organisms that exhibit tropism for the CNS, their presence at this site has little obvious benefit in promoting their life cycle and is frequently catastrophic for the host. For example, the presence of *C. neoformans* or *Listeria monocytogenes* in the brain might allow these organisms access to an environment that protects from the peripheral immune system, but without treatment they can cause fatal disease. Under these circumstances there is no obvious evolutionary advantage for these organisms that we can discern. In contrast, a limited subset of pathogens that includes HSV, African trypanosomes, *T. gondii* and Ebola, the ability to persist in neural tissues can directly aid in transmission or provide a sanctuary from which the pathogen can emerge to continue its infectious life cycle ([@bib110], [@bib216]). This principle might be relevant to HIV, which persists in microglia and astrocytes and could re-emerge, although this has yet to be proven.

Another consideration is that for many important infections of the CNS, humans are considered dead end hosts and the evolutionary basis for neurotropism in this host is unclear. Thus, West Nile Virus (WNV) and the flavivirus, Zika virus can cause acute and autoimmune encephalitides in adults and severe neurodevelopmental abnormalities in human fetuses. Neither of these viruses appears to spread from mammals back to mosquitoes and it is difficult to make a case that neurotropism in humans is critical for their success. Conversely, WNV is neurotopic in almost all birds (the natural host) and while it is asymptomatic in many species, its spread into new avian hosts indicated that those with CNS involvement generally succumb to infection ([@bib78]). The underlying molecular basis for these types of events is illustrated by the finding that glycosylation in the E protein of WNV results in increased peripheral viremia and virulence for birds and neuroinvasiveness in rodents ([@bib206]). It is plausible that strategies that promote neurotropism in a primary hosts provides an evolutionary advantage, which in an aberrant host results in disease.

Pathogen Interactions with Blood and Cerebrospinal Fluid Barriers and Access to the CNS {#sec1.4}
---------------------------------------------------------------------------------------

In the face of evolving (or accidental) neurotropism among pathogens that affect distinct compartments of the CNS (see [Table 1](#tbl1){ref-type="table"}), the presence of a barrier that limits microbial entry would have a significant selective advantage ([@bib31]). Indeed, the evolutionary conservation of the chemoprotective properties of the BBB and its role as a physical barrier to pathogen entry might indicate that its role in immune privilege evolved secondarily to these functions. In lower vertebrates and invertebrates this barrier is exclusively formed by glial cells. In higher vertebrates, it is established by polarized endothelial cells and the blood-cerebrospinal barrier (BCFB) and BBB exclude blood borne pathogens from the meninges, CNS parenchyma and ventricular system. The basis for this enhanced barrier function is the formation of specialized inter-epithelial and inter-endothelial tight junctions ([@bib124]). Intercellular tight junctions (TJs) composed of claudins and occludins join meningeal and choroid plexus (CP) epithelial cells, presumably limiting the ability of blood borne pathogens that cross their fenestrated endothelium from gaining access to the CNS. In contrast, parenchymal capillaries and venules exhibit both TJs and adherens junctions (AJs), which prevent permeation of solute, cells, and pathogens through paracellular routes. Mammalian BBB TJs and AJs connect BBB endothelial cells to each other and to cytoskeletal actin filaments. As in peripheral vascular beds and the gut, the lengths of actin fibers, which determine the integrity of TJs and AJs at the BBB, are regulated by Rho GTPases ([@bib41], [@bib107], [@bib57]). Thus, junctional complexes, in addition to barrier-stabilizing proteins expressed by abluminal pericytes and astrocyte endfeet, maintain the BBB (see [Figure 1](#fig1){ref-type="fig"} ).Figure 1Pathogen Mechanisms for Crossing the Blood Brain Barrier(A) The NVU is composed of astrocyte endfeet, pericytes, and endtothelial cells and the local production of type I IFNs has a major role in controlling opening of the BBB ([@bib58], [@bib132]). Micro-organisms utilize three main mechanisms to directly transit the BBB.(B) Trans-cellular route by which viruses or infected cells directly cross through EC ([@bib56]).(C) Para-cellular route whereby the breakdown of the tight junctions allows access of infected cells or extracellular pathogens to access the peri-vascular unit ([@bib196], [@bib205], [@bib231]).(D) Lytic mechanisms in which the ability to infect EC and lyse these cells allows pathogens to access the brain ([@bib125]).

The meningeal barrier effectively prevents the CNS entry of a majority of bacterial, fungal, and viral pathogens, while only neutrotropic viruses, molds, and certain parasites are able to readily access the CNS parenchyma (see [Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Viruses enter the CNS via multiple routes including retrograde migration along axons, transendothelial entry within the CSF compartment, or transcytosis across an intact BBB, and via delivery by infected mononuclear cells ([@bib56]). In the setting of certain viral infections TJ proteins, including ZO-1, VE-cadherin, occluding, and claudin 5, might be decreased and so provide a para-cellular route for pathogen or immune cell entry ([@bib24], [@bib122]; see [Figure 1](#fig1){ref-type="fig"}). This strategy to breach the BBB is relevant to the bacterial organisms *L. monocytogenes* and *N. meningitides*, which affect the CNS but use contrasting mechanisms to access this site. The ability of infected monocytes (the Trojan Horse hypothesis) to transport *L. monocytogenes* across the BBB ([@bib65]) provides a template for thinking about how other pathogens might access the CNS. For *N. meningitides*, the association of the meningococci with micro-capillaries with the lowest flow rates is a critical factor that allows access to the CNS ([@bib142]). In this setting, pilus-mediated adhesion of the meningococci to endothelial cells initiate a signaling cascade which results in the opening of intercellular junctions, allowing meningeal colonization ([@bib18], [@bib50], [@bib51]).Table 2Routes of Pathogen Entry to the CNSMechanismBacteriaFungalParasitesVirusesRetrograde transport along axonsNoneNoneNoneRabies virus ([@bib12])\
Herpes simplex viruses ([@bib127])\
West Nile virus ([@bib148])\
Venezuelan equine encephalitis virus ([@bib220])Transendothelial entry within CSF compartment*Group B strep* ([@bib122], [@bib198])\
*M. tuberculosis* ([@bib245])\
*L. monocytogenes* ([@bib63])\
*N. meningitides* ([@bib202])\
*T. pallidum* ([@bib38])*Angiostrongylus cantonensis* ([@bib11])Enteroviruses ([@bib56])\
Measles virus\
Chikungunya virus\
Venezuelan/Western equine encephalitis viruses ([@bib182])Paracellular entry at the BBB*L. monocytogenes (*[@bib63]*)*\
*Nocardia species* ([@bib13])*Candida albicans* ([@bib229])\
*Aspergillus niger*\
Zygomycetes\
Fusarium species\
*Pseudallescheria boydii*\
Pigmented molds\
*Histoplasma capsulatum*\
*Coccidioides immitis*\
*Penicillium marneffei*Herpes simplex viruses ([@bib56])\
West Nile virus\
Japanese encephalitis virus\
Human immunodeficiency virus\
PoliovirusTransendothelial entry at the BBBS. pneumococcus ([@bib109])*T. gondii* ([@bib125])\
*Taenia solium* ([@bib144])Influenza A ([@bib56]))\
West Nile virus\
Venezuelan/Eastern equine encephalitis viruses\
Rabies virusCNS entry via infected leukocytes (Trojan Horse)*L. monocytogenes* ([@bib65])*C. neoformans* ([@bib196])*T. gondii* ([@bib125])

Of the eukaryotic pathogens that affect the brain, *C. neoformans* and *T. gondii*, have the highest recognized incidence, with multiple mechanisms proposed for pathogen entry to the CNS. The ability to dissect these events in vivo is challenging and consequently in vitro studies with primary endothelial cells have been used extensively. Based on this approach, it has been proposed that both pathogens may enter the CNS via direct infection of brain microvascular endothelial cells (BMECs) and transcytosis from the blood to the brain via mechanisms that damage the BBB, either by disruption of TJs with subsequent edema, or via replication and lysis of BMECs ([@bib103], [@bib116], [@bib129], [@bib143], [@bib226]). In vitro, *C. neoformans* leads to alterations in barrier integrity to promote crossing of the BBB via a para-cellular route ([@bib143]) or due to transcytosis of infected mononuclear cells ([@bib196], [@bib205], [@bib231]). Monocytes infected with *T. gondii* are present in the blood and have been implicated as Trojan horses that allow this organism to access the brain ([@bib52]). Infection is also accompanied by the presence of numerous free parasites in the blood and the use of parasite mutants and multiphoton imaging indicate that parasite replication in and lysis of endothelial cells precedes invasion of the CNS ([@bib125]). One common theme that links several of the more recent studies is the ability to combine genetically modified pathogens with imaging techniques to visualize the BBB in vivo. This has provided the opportunity to the dissect the microbial factors that influence interactions with the NVU, and these approaches will be increasingly relevant to understand mechanisms of neurotropism in vivo.

Innate Immunity at the BBB {#sec1.5}
--------------------------

The NVU is composed of endothelial cells, pericytes, astrocytes, and neurons and it is now recognized that these cells mediate the initial responses to invading micro-organisms and these events are of particular importance to the control of meningeal pathogens ([@bib165]). The local expression of diverse pattern-recognition receptors (PRRs) by the BBB allows detection of pathogen associated molecular patterns (PAMPs) via coordination of interactions between infiltrating immune cells within perivascular spaces. The scavenger receptor MARCO mediates meningeal recognition of *N. meningitides* and leads to local production of IL-1 ([@bib28]). Similar events might also directly impact on permeability. For example, activation of Toll-like receptor (TLR)3 leads to barrier opening during WNV infection while TLR7 closes it ([@bib57], [@bib234]). Expression of cytokines downstream of innate immune signaling such as IL-1β and TNF-α also destabilize the barrier.

The type I IFNs are the hallmark of the innate response to viral infections and have potent anti-viral activities. They also have a context-dependent role in modulating the BBB and signaling via the type I IFN receptor, IFNα/βR (IFNAR) has a prominent role in stabilization of the BBB ([@bib57], [@bib132]). Recent studies have highlighted CNS region-specific roles of IFNAR signaling in other cellular members of the NVU, with astrocyte IFNAR signaling important for BBB integrity within the hindbrain during infection with WNV ([@bib58]). Both BMECs and astrocytes express the TAM receptors Mertk and Axl, which are receptor tyrosine kinases that bind Growth Arrest Specific 6 (Gas6) and Protein S. TAM signaling is enhanced by ligand interactions with phosphatidylserine displayed by apoptotic cells or enveloped viruses ([@bib20]). In animal models of WNV encephalitis MertK and IFNR signaling synergize to augment BBB integrity ([@bib155]). In all of these circumstances, IFNAR-mediated tightening of the barrier limited virus and immune cell entry, which prevented immunopathology within the hindbrain ([@bib58]). These events might help explain why the majority of patients with WNV encephalitis do not exhibit increased BBB permeability, as assessed via magnetic resonance imaging (MRI) ([@bib45], [@bib163], [@bib174]).

In contrast to WNV, certain flaviviruses, such as Japanese encephalitis virus, and other arboviruses that include the alphavirus Venezuelan Equine Encephalitis virus (VEEV), do lead to loss of BBB integrity ([@bib193]). VEEV, however, does not directly disrupt the barrier, because this occurs late in the course of infection and is associated with the infiltration of monocytes ([@bib33]). The related flavivirus, dengue can secrete nonstructural protein (NS)1, which disrupts the endothelial glycocalyx and compromise the integrity of peripheral vascular beds ([@bib185]). This mechanism might contribute to the rare instances when dengue does affect the CNS ([@bib207]), but it remains to be determined whether proteins secreted by neurotropic flaviviruses contribute to BBB instability during viremic stages of infection. Similarly, the HIV-1 protein Tat might induce disruption of the BBB via increased expression of platelet-derived growth factor subunit (PDGF-β) ([@bib169]). Thus, the effects of viruses on BBB function might occur at both luminal and abluminal sides of the NVU and thereby promote entry of free virions or virally-infected leukocytes to the CNS (see [Figure 2](#fig2){ref-type="fig"} ).Figure 2Viral Modulation of BBB FunctionViruses might impact on TJ integrity via direct and indirect mechanisms: (1) virus detection by brain endothelial TAM receptors in conjunction with type I IFN signaling enhances TJ integrity ([@bib155]); (2) nonstructural protein (NS)1 secretion by flaviviruses might decrease TJ integrity, increasing barrier permeability; (3) PRR signaling during viral infection of astrocytes leads to type I IFN expression which has been shown to improve BBB function via intercellular crosstalk with brain endothelium ([@bib57]); ([@bib180]); and (4) secretion of transactivator protein (TAT) during CNS infection with HIV-1 induces pericyte expression of PDGFβ, which disrupts BBB junctional proteins and promotes pericyte migration away from the vasculature ([@bib169]), ([@bib244]).

*Plasmodium falciparum* is a mosquito-transmitted parasite that causes cerebral malaria, a complex syndrome characterized by intravascular sequestration of infected erythrocytes and local inflammation within the microcirculation of the CNS. These events are associated with loss of BBB integrity with subsequent hemorrhage and cerebral edema (reviewed in [@bib101]). While *P. falciparum* does not directly infect the CNS, studies indicate that the parasite itself, through upregulation of barrier destabilizing inflammatory mediators, or through effects of secreted proteins, might impact on BBB function ([@bib77], [@bib176]). Thus, *P. falciparum*-infected erythrocytes induce human brain endothelial cells to express inflammatory molecules including CCL20, CXCL1, CXCL2, IL-6, and IL-8, and intercellular adhesion molecule (ICAM)-1 ([@bib223], [@bib222]). In murine models of cerebral malaria that use the *P. berghei* ANKA strain, blockade of lymphocyte function-associated antigen (LFA) 1, which binds ICAM-1, and treatment with liposomal corticosteroids, which stabilizes TJ integrity, both reduced BBB disruption ([@bib159], [@bib233]). These latter studies illustrate the principal that targeting the effects of pathogens at the BBB might provide an opportunity for adjuvant therapeutic approaches to prevent or manage local immunopathology.

Mechanisms of Innate and Adaptive Protective Immunity in the CNS {#sec1.6}
----------------------------------------------------------------

Infections of a host with neurotropic pathogens typically occurs at sites such as the skin, mucosa, gut, or lung, via inoculation, ingestion, or inhalation followed by replication and eventual dissemination to the CNS. The temporal nature of these events ensures that the initial activation of innate arms of the immune system occurs in the periphery and influences the generation and expansion of pathogen specific T cells that promote cell intrinsic mechanisms that limit microbial replication. As noted earlier, a wide range of PRRs are expressed by all cells of the NVU and the choroid plexus (CP), and by neuronal and non-neuronal cells within the CNS. These innate sensors direct the local recruitment of leukocytes (most commonly neutrophils, T cells, B cells, monocytes, and dendritic cells), required for microbial control. There are several well-characterized portals of entry for inflammatory cells into the brain, including the fenestrated vasculature within the subarachnoid space and CP, and across epithelial and ependymal cells or astrocyte endfeet of the CP and BBB respectively ([@bib72]). In this section, we will detail the cellular and molecular mechanisms of innate and adaptive immune responses that control pathogen invasion, replication and persistence within the CNS, citing recent reviews for well-established discoveries.

### Innate Immunity and Neuro-protection {#sec1.6.1}

For many pathogens that are restricted to the NVU, access to the CNS parenchyma is generally prevented by robust innate immune responses within the meninges and ventricular system ([@bib165]). Interactions of infected myeloid cells or free pathogens with the vasculature at these sites lead to expression of adhesion molecules, including vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 or -2, and chemoattractants CXCL2, leukotriene B4, and complement component C5a, by epithelial or endothelial barriers that recruit neutrophils and monocytes ([@bib165]). There are high constitutive levels of complement proteins present in the CNS, which contribute to normal neuronal function and microglial activity, but less is known about their function during neural infection ([@bib230]). Indirect evidence for their role in the brain is provided by the observation that patients with primary immune deficiencies that affect complement are uniquely susceptible to meningitis caused by *N. meningitides* ([@bib133]). Further, analysis of human samples of cerebral aspergilosis indicates the highest levels of C3 were associated with fungal control but also that the hyphal forms of this organism were resistant to C3 deposition ([@bib188]).

The receptor CCR2 and its ligand CCL2 (aka monocyte chemo-attractant protein 1) plays a major role in the mobilization of monocytes and neutrophils. The infiltration of CCR2-expressing Ly6C^hi^ monocytes has been observed in animal models that study the CNS involvement with *T. gondii*, WNV, or murine hepatitis virus (MHV). In these systems, CCR2 inactivation is associated with decreased leukocyte trafficking and activation of immune cells within the CNS, and a reduced ability to control these pathogens ([@bib15], [@bib22], [@bib42]). The presence of anti-inflammatory (M2) macrophages or microglia in the CNS is subject of an ongoing debate, but in a murine model of chronic toxoplasmosis, a subset of infiltrating macrophages express canonical M2 markers: CD206 (the mannose receptor), the chitinase AMCase and arginase ([@bib161]). While these cells might be expected to have a role in resolution of inflammation, mice that lack AMCase have a higher parasite burden in the CNS. Based on these results, and those of in vitro studies, it has been proposed that these M2-like populations might be specialized to target the cyst stage of *T. gondii* ([@bib161]). These reports, in diverse experimental models, highlight the context dependent contribution of chemokine-mediated recruitment of myelomonocytic cells for protective immune responses within the CNS.

### Neural Cell Responses to Infection {#sec1.6.2}

All neural cell types, including neurons, astrocytes, oligodendrocytes, and microglia, are capable of initiating and responding to inflammatory responses during infection ([@bib160]). Neurons are electrically excitable cells that process and transmit information via electrical and chemical signals. Astrocytes and oligodendrocytes are glial cells that maintain CNS homeostasis, improve neurotransmission via chemical or physical insulation, and support and protect neurons (reviewed in [@bib111]). Microglia are ontogenetically distinct members of the reticuloendothelial system that function as tissue macrophages within the CNS (reviewed in [@bib48]). Microglia and resident dendritic cells are among the first responders to pathogen invasion, responding to PAMPs via liberation of pro-inflammatory cytokines and clearance of infected cells and debris ([@bib67], [@bib227]). All of these neural cells express TLRs, Nod-like receptors (NLRs), RIG-like receptors (RLRs), mitochondrial anti-viral signaling (MAVS) ([@bib254]), AIM2-like receptors (ALRs), C-type lectin receptors, and cytokine receptors (reviewed in [@bib119]). Activation of many of these innate immune pathways converge on expression of type I IFNs and mononuclear cell chemoattractants (CCL2, CCL5, and CXCL9-11) and there are many studies that illustrate the relevance to CNS infection. The extended TLR3 signaling pathway is critical in mediating resistance to HSV encephalitis in humans and in mice ([@bib4], [@bib37], [@bib68], [@bib95], [@bib130], [@bib136], [@bib179], [@bib195], [@bib252]). Other pathways mediate direct anti-pathogen effects, and MAVS sensing of bunyavirus in neurons leads to death of infected cells ([@bib158]). In contrast, sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defense in the CNS ([@bib191]).

Regional or cellular heterogeneity in innate immune responses of neurons and astrocytes, in particular, might underlie observed differences in pathogen spread, persistence, and immunopathology in different regions of the CNS. Indeed, cortical neurons have low levels of RIG-I, MDA5, ISG54, and ISG56 and consequently are more permissive to WNV than those in the hindbrain ([@bib55]). Of interest, cerebellar pathology in patients with WNV encephalitis is associated with poorer prognosis ([@bib1]). Further studies are needed to determine whether this subset of patients have underlying defects in hindbrain innate immune function that increase their susceptibility to infection. Differences in baseline expression of genes involved in responsiveness to type I IFN and in susceptibility to viral infections might also help to explain the tropism of viruses for different cell types and regions. The expression of the innate genes Ifnα, Tlr7, Ifit1, Ifit3, Mda5, Ifi44l, Mx1, Rsad2, Stat1, and Oas1 are elevated in murine cerebellar granule cell neurons and astrocytes, compared with cortical neurons and astrocytes ([@bib44], [@bib58]). Despite lower basal expression of many IFN stimulated genes in neurons, basal expression of the type I IFN themselves is elevated in primary hippocampal neurons which is important for early control of measles virus ([@bib39]). While infected neural cells might themselves restrict pathogen replication and dissemination, they can also recruit peripheral myeloid and lymphoid cells to localized sites of infection ([@bib154]). Regional or cellular heterogeneity in cytokine or chemokine expression by neurons and astrocytes might also contribute to different local outcomes. Thus, IL-1 is generally regarded as pro-inflammatory, but during WNV encephalitis IL-1 promotes BBB expression of CXCL12, which limits immunopathology via localization and modulation of T cell fates within peri-vascular spaces ([@bib70]).

In order to be able to disseminate, access, and persist in the CNS, neutrotropic organisms need to be able to evade the innate effector mechanisms that are deployed against them. The principle that the pathways targeted by pathogens are those that matter most is illustrated by the array of mechanisms used by neurotropic organisms that target the type I and II IFNs. This is relevant to certain arboviruses which have evolved mechanisms to inhibit type I IFN signaling, which allows survival of infected neurons ([@bib194]). The type I IFN receptor, IFNAR, activates STAT1/2 via TYK2 and JAK1 signaling and WNV inhibits TYK2 activity, while the related flavivirus, Zika virus degrades human STAT2 ([@bib27]). Similarly, VEEV evades activity of the interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) that blocks translation of virion-delivered virus-specific RNAs ([@bib89], [@bib108]). Of relevance to the JAK/STAT pathway, *T. gondii* secretes an effector molecule into its host cell that recruits a host chromatin repressor complex, which blocks the ability of IFN-γ to mediate transcription through STAT1 ([@bib80], [@bib173]). That diverse organisms have multiple strategies to target JAK/STAT signaling is consistent with the key role of the IFNs in mediating resistance to these neurotropic pathogens and is relevant to many other innate sensing and effector mechanisms.

### Astrocytic Responses to Infection {#sec1.6.3}

Astrocytes are considered the most numerous cell type in the CNS and, while frequently defined by the expression of the intermediate filament glial fibrillary acidic protein (GFAP), this is a heterogenous cell type with distinct functions in different anatomical regions of the CNS, associated with neuronal health and maintenance. This topic is covered in depth in this issue by [@bib134]. The use of Aldh1l1-reporter mice in conjunction with screening for differential expression of surface antigens was used to identify five distinct subpopulations of Aldh1l1+ astrocytes within the olfactory bulb, cortex, brainstem, thalamus, and cerebellum that exhibit unique genetic signatures, including a subpopulation that exhibits higher levels of expression of immune molecules ([@bib247]). Similarly, a comparison of cerebellar with cortical astrocytes revealed that cerebellar cells exhibit higher expression of genes involved in TJ and AJ signaling, supporting their differential effects on BBB stability ([@bib58]). Whether these subpopulations also exhibit differences in susceptibility to infection, inflammatory responses or effects on BBB function remains to be determined.

The prominent hypertrophy of astrocytes associated with infections of the CNS and the ability to activate these cells in vitro with IFNs to control pathogen replication led to the idea that these cells would have an important role in the host response to infection. The use of lineage targeting approaches to delete the IFNAR on astrocytes increases WNV infection and immunopathology within the hindbrain ([@bib58]), while the removal of STAT1 from these cells results in increased susceptibility to toxoplasmic encephalitis (TE) ([@bib98]). Interestingly, a genetic screen to identify host factors that enhance the activation of STAT1 revealed that the orphan nuclear hormone receptor TLX, expressed in neural stem cells and astrocytes, is a modifier of STAT1 activity and is required for resistance to *T. gondii* ([@bib14]). Although astrocytes lack the major known IFN-γ-induced pathways that target *T. gondii* ([@bib91], [@bib105]), two of the IFN-γ-inducible 47 kD Immunity Related GTases (IRGs) are required for murine astrocytes to eliminate *T. gondii* in vitro ([@bib61], [@bib152]). Humans lack IRGs but the p67 guanylate-binding proteins (GBPs) have analogous functions ([@bib140]) and GBP2 is required for parasite killing by murine astrocytes in vitro ([@bib61]). These proteins are part of a coordinated response that intersects with autophagic processes that lead to parasite control ([@bib61], [@bib167], [@bib228], [@bib246]). From a broader perspective, these findings highlight a major knowledge gap in our understanding of how astrocytes and neurons respond to the IFNs to mediate control of diverse pathogens. To date, almost 2,000 IFN stimulated genes (ISG) have been identified in human and mouse cells but few of these genes have been characterized in the context of infection and improved methodologies to dissect the anti-microbial activities in different neural cell types are needed.

In the context of sterile or microbial-induced CNS injury, astrocytes start to proliferate, increase expression of GFAP and undergo changes in morphology (termed astrogliosis) that allows them to form dense networks or "glial scars" at sites of damage. In mice challenged with *Staphylococcus aureus* or *T. gondii*, reactive astrocytes are prominent, but the absence of GFAP limits glial scar formation and the ability to restrict inflammation, which leads to pathogen spread ([@bib211]). Similarly, when compared to wild-type controls, mice with astrocyte lineage-specific deletion of the cytokine receptor gp130, exhibited increased astrocyte apoptosis and inflammation. Although these mice control parasite numbers, they exhibited a more extensive inflammatory response and increased susceptibility to the chronic phase of infection ([@bib66]). This phenotype is recapitulated with the loss of TGF-β signaling in astrocytes, which did not affect parasite burden but resulted in increased inflammation and neuronal damage ([@bib40]). These studies indicate that the extensive gliosis associated with many CNS infections is part of a conserved response to local injury (analogous to granuloma function) that provides a physical barrier to limit tissue damage and isolate areas of pathogen replication.

### Mechanisms of Adaptive Protective Immunity {#sec1.6.4}

In the majority of CNS infections discussed above, the initial priming of T cell responses that contribute to pathogen control are generated in the periphery. As a consequence of pathogen replication in the brain, pathogen-specific T cells traffic to the CNS and are able to gain parenchymal access. While there are a limited number of helminth infections that are associated with T helper 2 (Th2) responses that affect the CNS (neurocystocercosis and aberrant migratory nematodes), most clinically relevant infections of the CNS are viral, bacterial, fungal, or protozoan, and it is not surprising that adaptive resistance to these organisms in the brain is mediated by CD4^+^ and CD8^+^ T cells that produce IFN-γ. There is a strong dogma that initial entry of pathogen-specific T cells into the CNS is dependent on local antigen presentation which influences their local expansion and retention ([@bib225]). This is a complex topic, and the reports that activated T cells, regardless of antigen specificity, can traffic to the uninflamed CNS ([@bib236]), suggests the presence of a mechanism that allows surveillance of the CNS that might precede and potentially limit pathogen entry. In contrast, during TE the activation and expansion of T cells specific for a non-microbial antigen did not result in their entry to the CNS ([@bib241]). The observation that activation alone is not sufficient for T cell entry to the inflamed CNS is consistent with the idea that there might be a licensing mechanism that influences T cell entry ([@bib171]).

Regardless, once access to the CNS has been achieved, these T cell populations need to find their relevant targets and mediate local pathogen control (see [Figure 3](#fig3){ref-type="fig"} ). Mice infected with *T. gondii* or LCMV have provided tractable models for intra-vital imaging of how T cells in the CNS interact with infected cells and other antigen presenting cells. Analysis of the movement of parasite specific effector CD8^+^ T cells in the CNS of mice with TE revealed that these cells did not display a directed migration, rather their behavior was reminiscent of the search strategies utilized in nature to find rare targets ([@bib92]). One unexpected outcome of these studies was the idea that locally produced chemokines did not establish gradients to attract effector T cells, but rather provided motogenic signals to promote T cell movement required for the search strategy ([@bib92]).Figure 3Effector Mechanisms Used by T Cells to Control CNS Infection(A) The ability of pathogen-specific CD4^+^ and CD8^+^ T cells to exit the circulation, cross the BBB, and access the parenchyma precedes the search for relevant infected CNS-specific targets.(B) The local production of IFN-γ by CD4^+^ and CD8^+^ T cells has a prominent role in the activation of STAT1 and the anti-microbial activities of astrocytes and microglia. While CD8^+^ T cells can interact with infected astrocytes and microglia to mediate elimination of infected cells or control of pathogen replication it is unclear whether their interactions with neurons is direct through MHC-TCR interactions or indirect through the activation of microglia.(C) The development of Th17 responses characterized by the production of IL-17 and/or GM-CSF is correlated with the development of immunopathology and the recruitment of inflammatory monocytes.

Based largely on in vitro and correlative studies, there has been a long held belief that microglia are likely to have a prominent role in the local response to infections either as antigen-presenting cells or as phagocytes capable of killing microorganisms. The interactions of pathogen specific T cells with accessory cells (DC and/or microglia has also been visualized using intravital imaging of CD8^+^ T cells responding to infection with *T. gondii* ([@bib115], [@bib198]). During infection with LCMV, microglia are a major reservoir of infection, and antiviral CD8^+^ T cells can stably engage microglia in an MHC I-dependent manner. In contrast, CD4^+^ T cells have less sustained interactions with microglia, likely as consequence of the relative abundance of cognate peptide--MHC I versus MHC II complexes ([@bib97]). A functional role for microglia in modulating CD8 T cell responses was illustrated via pharmacological deletion of microglia during dengue virus infection that resulted in reduced CD8^+^ T cell responses and increased viral replication ([@bib224]). The fundamental advances in understanding microglial development combined with ability to visualize how these cells interact with pathogens and other immune cells and the use of genetic approaches to manipulate microglial immune function will provide the opportunity to better understand the contribution of these cells to resistance to infection or resolution of local inflammation.

T cell production of IFN-γ induces a wide range of anti-microbial effector molecules, often in a cell-type-specific fashion (see earlier sections on astrocytes and neurons) and is a key cytokine for neuroinfectious diseases ([@bib87]). This principle was established in murine models of toxoplasmosis in which CD4^+^ and CD8^+^ T cells in the CNS produce IFN-γ that, in combination with other effectors such as TNF-α and CD40L, mediate local parasite control ([@bib62], [@bib81], [@bib190], [@bib215], [@bib248]). In this system, in addition to effects on astrocytes, the production of IFN-γ drives local macrophage activation, with production of toxic oxygen intermediates such as nitric oxide (NO) required to control intracellular parasites ([@bib60], [@bib162], [@bib199]).

The neuroimmunology literature has focused on the contribution of T helper 17 (Th17) cells to the development of autoimmune pathology ([@bib126]), but less is known about their function during CNS infection. Perhaps the strongest indication that these cells are protective in the CNS is in the setting of fungal infections where there is a high prevalence of invasive candidiasis of the brain in patients with primary genetic defects in CARD9, an adaptor required for the development of Th17 responses ([@bib3], [@bib84], [@bib94]). While these patients have reduced Th17 responses, the observation that other genetic deficiencies associated with diminished IL-17 production are not susceptible to Candida suggest that another mechanism might underlie susceptibility. Indeed, these patients also have a reduced ability to produce GM-CSF, a cytokine associated with Th17 responses that promotes macrophage and microglial function. The idea that a reduced ability to make GM-CSF might underlie susceptibility to invasive candidiasis is supported by the success of GM-CSF in these patients as an adjunctive therapy with anti-fungal agents ([@bib79]). Because T-cell-derived GM-CSF is important in the recruitment of CCR2^+^ inflammatory monocytes to the CNS during experimental allergic encephalomyelitis (EAE) ([@bib53]), this pathway might be relevant to models in which monocytes are important for local control of CNS infection ([@bib15], [@bib22], [@bib42]).

### Adaptive Mechanisms to Target Neurons {#sec1.6.5}

The neuron, as a long-lived cell with a unique biology that ensures that a single cell can traverses extensive areas of the CNS, seems an ideal refuge for many pathogens. Indeed, several viruses in the CNS are not cytolytic and have evolved strategies to interfere with anti-microbial pathways and to remain latent in neurons. This is illustrated with HSV in which latency associated transcripts generate miRNAs that target immunomodulatory genes that facilitate viral latency ([@bib25]). This ability to target neurons is not exclusive to viruses and a select group of apicomplexan parasites (notably *T. gondii*) have specialized cyst stages that persist in neurons. It has been proposed that the cellular stress associated with the immune response drives cyst formation and extracellular adenosine (likely released from damaged cells) signaling through CD73 promotes cyst formation ([@bib141]). It is notable that cysts are typically restricted to neurons, but the loss of STAT1 in astrocytes results in cyst formation in these cells in vivo, a finding that suggests IFN-γ can actively prevent cyst formation ([@bib98]). The ability to study how neurons respond to infection in vivo remains challenging but there are two examples where the ability to genetically modify pathogens to express the Cre recombinase combined with host reporters has provided novel tools that have advanced this topic. Thus, the use of rabies that express Cre has shown that the majority of RABV-infected neurons survive infection and clearance and these have been transcriptionally profiled ([@bib85]). Similarly, the use of *T. gondii* strains that secrete Cre into host cells has been used to visualize neurons infected with Toxoplasma ([@bib32]).

While there is a role of type I IFNs in limiting viral replication in neurons, there are open questions about the mechanisms used by T cells to target these cells. For example, the non-cytolytic clearance of Measles (the cause of sub-acute sclerosing panencephalitis) and Sindbis from neurons is IFN-γ dependent ([@bib21], [@bib178]) and there appears to be a bystander role for CD4^+^ T cells in some of these events ([@bib208]). In "carrier mice" that have an established LCMV infection in neurons, there is a literature that identifies "therapeutic" CD8^+^ T cells as being important in elimination of this virus pool through the production of IFN-γ that licenses microglia to purge virus, present antigen, and amplify the local antiviral T cell response ([@bib97], [@bib172], [@bib183]). How microglia mediate these effects is uncertain, but is associated with a number of STAT1-dependent processes and the presence of a GM-CSF signature ([@bib97]).

While there has been a long-held belief that neurons express no MHC class I (which would make them an ideal cell type to evade CD8^+^ T cells), the application of more sensitive technologies has led to the recognition that different subsets of these cells can express MHC class I in the developing and adult brain and that these molecules have a role in neurological function ([@bib54], [@bib204]). There are reports of the induction of neuronal class I during infection ([@bib166]), but there remains a major knowledge gap in our understanding of whether neuronal antigen presentation influences resistance or susceptibility to infection in vivo. There is in vitro and in vivo evidence for CD8^+^ T cells interacting directly with infected neurons during Theiler's virus, LCMV, Borna and picornavirus infection ([@bib43], [@bib106], [@bib149], [@bib187]) and there is evidence that the ability of HSV to inhibit class I expression in neurons in basal ganglia is key to avoid CD8^+^ T cell responses ([@bib175]). Unexpectedly, imaging studies indicate that CD11c^+^ cells (likely microglia or DC), but not parasite-specific CD8^+^ T cells, frequently interact with cysts of *T. gondii* ([@bib115], [@bib198]). The ability to generate parasites with altered expression of stage-specific antigens (cyst versus non-cyst), has demonstrated that antigens associated with latency do not trigger the same immune responses as those produced during active infection ([@bib120]). These results highlight an immune evasion strategy to promote parasite persistence that would likely be relevant to many pathogens that have latent stages.

### Tissue-Resident Memory Populations in the CNS {#sec1.6.6}

For many of the pathogens discussed here, the control of the acute phase of the disease is mediated by T cells and as antigen load is reduced the number of pathogen-specific T cells contract. One consequence of these events is the generation of a long-lived pool of tissue-resident memory T (Trm) cells, which reside in barrier tissues like the lung, skin reproductive tract, and gut where they maintain post-infection homeostatic surveillance ([@bib6], [@bib200], [@bib210]). Identification of these populations has been based on the expression of CD103 (the αE integrin) and CD69 (a proximal marker of TCR activation and tissue retention). In several models, viral-specific CD8^+^ Trm are maintained in the CNS in the absence of detectable virus. Thus, in mice challenged with neurotopic influenza virus, CD8^+^ T cells were present at this site 320 days after infection ([@bib93]). Similarly, following clearance of VSV from the brains of mice, clusters of CD103^+^ CD8^+^ T cells persist at likely sites of previous infection ([@bib232]). LCMV-specific brain Trm are also found close to epithelial cells of the ventricular lining, within the choroid plexus, and in the meninges ([@bib209]). The ability to generate CNS-specific Trm is not specific to viral infection or dependent on antigen clearance and increasing chronicity of toxoplasma infection is associated with an enrichment of cells that co-express CD103 and CD69 and which are transcriptionally similar to VSV-specific Trm ([@bib131]).

With the recognition that pathogen-specific Trm populations are present in the CNS there has been interest in understanding the processes that influence their formation. Following WNV infection, the production of TGF-β results in increased expression of CD103 by CD8^+^ T cells, which allows a large pool of resident memory T cells to be maintained ([@bib86]). During acute infection with the mouse polyoma virus the high-affinity effector cells give rise to high-affinity Trm. Functional studies have shown that virus-specific Trm have a TCR affinity that is approximately 20-fold higher in CD8^+^ T cells derived from the brain versus those of the spleen ([@bib75]). This selection for high TCR affinity could improve the ability of Trm to detect infected cells that express low levels of pathogen derived MHC-peptide complexes. Concrete evidence that Trm are of functional significance in the CNS is provided by the use of mice that had cleared LCMV. In this setting, intracerebral inoculation of virus resulted in LCMV specific CD8^+^ Trm entering cell cycle and mediating viral control independently of peripheral CD8^+^ T cells via production of IFN-γ and perforin ([@bib209]). These types of experimental systems will help understand the rules that govern these populations and aid with the development of strategies to promote the generation of Trm that could limit pathogen reactivation within the CNS.

Limiting Inflammation in the CNS: Immunomodulatory Cytokines, Inhibitory Receptors, and Treg Cells {#sec1.7}
--------------------------------------------------------------------------------------------------

While the presence of inflammatory cells in the CNS is critical for local control of infection, this immune response is often pathological and regardless of the initiating factor, will frequently converge on pathways that induce neurotoxicity. A variety of models can be used to distinguish the immune processes required for resistance to infections from those that induce bystander damage or post-infectious sequelae. Indeed, there are numerous examples in which altered chemokine signaling or reduction of T cell numbers in the setting of CNS infection results in unexpected but improved outcome ([@bib34], [@bib46], [@bib189]).

During murine infections with WNV, CCL-dependent accumulation of monocytes is associated with development of pathology ([@bib9], [@bib83], [@bib135]), whereas in mice infected with HSV, innate cell infiltration is associated with fatal disease ([@bib139]). Similarly, the CCCR2-dependent monocytes associated with Theiler's murine encephalitis virus (TMEV) mediate the demyelination that characterizes this infection ([@bib16]). The intra-cerebral challenge with LCMV results in immunopathologic CD8^+^ T cell responses in the meningeal compartment that is characterized by the recruitment of neutrophils and monocytes that mediate the vascular injury and the onset of seizures ([@bib121]). In the latter model, the type I IFN have a key role in priming the pathological monocyte response ([@bib164]) and can lead to edema, neuronal death, and herniation ([@bib147], [@bib146]). A similar phenotype is apparent in mice infected with picornovirus ([@bib106]) and in murine models of cerebral malaria. In the latter system, CD8^+^ T cell responses are associated with alterations in TJs and vascular breakdown in the meninges and parenchyma, resulting in edema, neuronal cell death within the brainstem, and cerebral herniation ([@bib104], [@bib217]), reminiscent of the disease process observed in humans ([@bib203]). Thus, inflammation that results in bystander neuronal death or damage to regions of the brain that control autonomic functions can significantly impact host survival.

Another possible consequence of local inflammation is the release of autoantigens and breakdown of tolerance that might lead to a bona fide autoimmune process mediated by T or B cells. For example, after HSV encephalitis the development of auto-antibodies specific for N-methyl-D-aspartate receptor (NMDAR) can lead to a post-viral encephalitic syndrome characterized by seizures and psychosis ([@bib100], [@bib238]). Similarly, damaged oligodendrocytes during MHV infection promote the recognition of Myelin Basic Protein by auto-reactive CD4^+^ T cells, leading to epitope spreading and the development of demyelinating disease that is reminiscent of MS ([@bib150]). It seems likely that the true prevalence and consequences of these types of post-infectious sequlae in patients is not fully appreciated ([@bib124]).

While the development of neuroinflammation is important to respond to local infections, there are also conserved regulatory processes that help with the resolution of CNS inflammation or which exist to limit the development of overwhelming immune pathology ([@bib76]). The cytokine IL-10 is important negative regulator of inflammation, which acts directly on DCs, microglia, and macrophages to downregulate expression of costimulatory molecules and the ability to present antigen and produce inflammatory cytokines. While there are multiple sources of IL-10, in the setting of many infections, the ability of T cells to produce IL-10 provides a critical negative regulatory loop that prevents T cell hyper-activity ([@bib49]). In mice chronically infected with *T. gondii* the absence of IL-10, leads to lethal CNS inflammation mediated by CD4^+^ T cells and characterized by elevated IL-17 production ([@bib240]). For LCMV, the presence of IL-10 promotes viral persistence in the CNS ([@bib30]), while IL-10 deficient mice infected with Sindbis develop an aberrant Th17 response associated with neuronal cell death ([@bib128]) and IL-10 derived from CD8^+^ T cells protect from pathology during coronavirus infection ([@bib221]).

IL-27 is a cytokine produced by microglia and other macrophage populations in the inflamed CNS that has emerged as having an important role in limiting neuroinflammation. Thus, in the absence of IL-27 signaling, mice infected with *T. gondii*, Coronaviruses, or Sindbis are characterized by elevated production of IL-17 and GM-CSF in the CNS, which correlate with the development of T cell-mediated immune pathology ([@bib59], [@bib128], [@bib213], [@bib219], [@bib250]). While there is good evidence that IL-27 can directly limit T cell production of IL-17 and GM-CSF, it can also promote T cell production of IL-10, Treg cell responses, and T cell expression of inhibitory receptors ([@bib64], [@bib90], [@bib99]). The enhanced CNS pathology observed in the absence of IL-10 or IL-27 suggests that while they might target different cell populations and have fundamentally different mechanisms of action, these cytokines are shared components of an immunoregulatory cassette that acts to temper T cell mediated CNS inflammation.

Many of the overarching principles that have guided the study of "inhibitory receptors" (PD-1, PD-L1, CTLA-4, TIGIT, Tim-3, LAG-3) that provide cell-intrinsic signals that limit T cell responses emerged from studies of peripheral responses to LCMV ([@bib114], [@bib239]). One model suggests that serial engagement of T cells in the context of persistent antigen results in a hierarchical acquisition of inhibitory receptors that results in "exhaustion" but allows détente between viral persistence and the pathological consequences of T cell responses ([@bib239]). During neural involvement of LCMV there is increased T cell expression of PD-1 in the CNS ([@bib23]), but there is a paucity of studies that have dissected the impact of inhibitory receptors on local responses in the brain. Similarly, during HSV infection in mice, viral-specific CD8^+^ T cells express increased levels of LAG3, TIM3, and PD-1, which is associated with an inability to control viral replication in the CNS ([@bib153]). During toxoplasmosis, parasite-specific CD8^+^ T cells recruited to the brain downregulate their ability to produce IFN-γ and granzyme over time, which correlates with increased expression of PD-1, LAG3, and TIGIT ([@bib98], [@bib241]). The potential significance of these observations is emphasized by the report that the blockade of PD-1 during the chronic phase of this infection results in enhanced parasite clearance ([@bib19]). This is clearly a topic where additional studies are required to determine the relative impact of diverse inhibitory receptors on anti-microbial effector activities and whether they promote microbial persistence.

Treg cells are defined by the expression of the transcription factor Foxp3 and maintain homeostasis within the T cell compartment through direct antagonism of T cell function, as well as effects on DC populations ([@bib117]). These suppressive activities are attributed to multiple mechanisms that include the production of IL-10 as well as expression of inhibitory receptors. Treg cells are absent from the uninflamed CNS, but during infection are co-recruited with effector T cells. Given their prominent role in other inflammatory diseases settings, there have been questions about whether these regulatory populations contribute to the outcome of CNS infection. In mice infected with measles virus, expansion of Treg cells resulted in enhanced viral levels in neurons while the transient depletion of Foxp3^+^ Treg cells led to expanded populations of virus-specific CD8^+^ T cells and improved viral control ([@bib192]). Following challenge with MHV, virus-specific Treg cells are present in the CNS and have a role in limiting immune-pathology ([@bib5]). These MHV-specific Treg cells inhibit the expansion of viral specific CD4^+^ T cell effector responses, which is associated with reduced microglial activation and decreased mortality, without affecting virus clearance ([@bib253]). Intravital imaging of Treg cells has shown that they are highly migratory in secondary lymphoid tissues but during TE they appear restricted to perivascular regions where they form sustained interactions with DC ([@bib170]). While it is possible that Treg cells might lose expression of Foxp3 as they migrate into the CNS, this exclusion from the parenchyma might allow enhanced effector cell function within the brain. This observation also supports the idea that perivascular compartments represent a site where regulation of T and B cell effector functions occurs ([@bib70], [@bib69], [@bib181]).

Future Directions {#sec1.8}
-----------------

### Can CNS Infection Be Beneficial through Innate Immune Activation? {#sec1.8.1}

While persistent immune activation in the brain is associated with a number of infectious, autoimmune, and neurodegenerative conditions, it is unclear whether all inflammatory pathways are detrimental for brain function. There is evidence that many of the innate immune molecules discussed above in the context of infection, are required for normal CNS development, function, and repair. Ontology studies have shown that microglia are derived from erythromyeloid precursors in the yolk sac, migrating, and proliferating within the CNS early during embryonic development, via processes that requires CSF-1R, its ligand IL-34 and TGF-β. Mice deficient in these molecules exhibit severely decreased numbers of microglia in many brain regions ([@bib48]). Activated, CD68^+^ microglia are normally present in the developing forebrain subventricular zone, where neural precursors reside. Treatment of mice with minocycline, a broad-spectrum antibiotic that decreases microglia activation, or genetic deficiency in CSF-1R, is associated with disruption of periventricular cellular architecture, decreased neurogenesis, and oligogenesis, the latter of which produces myelinating cells of the CNS ([@bib73], [@bib74]). Similarly, TLRs and TAM receptor signaling is critical for adult neurogenesis within the dentate gyrus, a process that is essential for learning and memory ([@bib113], [@bib145], [@bib157]). There are also numerous reports that link the microbiota with neural development that is covered in depth in this issue by [@bib249] but is exemplified by the link between microbiome-driven TLR4 signaling in EC that leads to cerebral cavernous malformations ([@bib218]). Neuronal differentiation is further associated with expression of IRF9, IFNAR, and STAT1 ([@bib74]). Moreover, mice deficient in IFNAR signaling develop defects in neuronal autophagy, suggesting a critical role for this molecule in CNS homeostasis ([@bib71]). TAM signaling within neural cells might also exhibit synergistic effects on type I IFN-mediated cellular processes ([@bib155]), supporting the notion that baseline activation of IFNAR supports normal brain function.

Previous sections have emphasized the development of protective inflammatory response and the mechanisms that limit pathology but there are also regenerative processes that serve to restore neural function. Given the role of immune pathways in normal neuronal development, it is not surprising that innate responses triggered during infection are also involved in CNS homeostasis, repair, and recovery. Chemokines can also promote expression of anti-inflammatory molecules and growth factors, such as transforming growth factor (TGF)-β, insulin growth factor (IGF)-1, fibroblast growth factor (FGF)2, and platelet derived growth factor (PDGF)-A ([@bib47], [@bib235]). Myeloid cells are instrumental in CNS repair by virtue of their phagocytic and cytokine expression functions ([@bib137]) ([@bib96]). Activation of PRRs on myeloid cells, including TLRs 1 and 2, CR3, Dectin-1 and 2, promotes phagocytosis, oxidative burst, and cytokine production. Phagocytic receptors CD14, CD36, TREM2, and TLR4 are critical for pathogen clearance while complement opsonins C1q, C3 and iC3b and PRRs, TAMs, and TREM2 facilitate removal of apoptotic cells (reviewed in [@bib48]). Studies using mice deficient in TREM2 or TLR4 demonstrate that lack of debris elimination results in defects in repair of demyelination and axonal regeneration, respectively ([@bib35], [@bib186]). CNS region-specific effects of macrophage-specific PRRs have also been observed; activation of dectin-1, a C-type lectin receptor, promotes optic nerve, but not spinal cord, axon regeneration via Erk1/2 MAP-kinase signaling and cAMP response element-binding protein (CREB) activation, while TLR2 activation has the reverse effects during injury of these two CNS regions ([@bib8], [@bib82]). Cooperative signaling between CD14, TLRs, and dectin-1 in activated myeloid cells also leads to expression of type I IFN, which can limit glial scar formation, remove degenerating axons and promote their regrowth ([@bib102], [@bib168], [@bib251]). The identification of innate immune pathways that promote recovery from pathogen-mediated brain injury could provide new targets for the development of therapies to treat non-infectious CNS disorders.

### Can Immune-Mediated Strategies Be Developed to Better Manage CNS Infections? {#sec1.8.2}

From a clinical perspective, the management of patients with neuroinfectious disease is complicated by the lack of treatment options available to suppress inflammation without compromising protective responses. Moreover, the concept that boosting anti-pathogen responses in the CNS is a clinically viable strategy runs counter to the perception that inflammation of the CNS should be avoided. The use of clinically relevant models described throughout this review have already provided insights into the balance between stringent regulation of immune cell access to the CNS and the need for anti-pathogen immunity. The natural history of human infections and the use of antibody-based therapies to treat inflammatory diseases illustrates the importance of surveillance and effector mechanism that are relevant to immunity in the CNS but also the ability to balance therapeutic dose to allow clinical benefit versus compromise of CNS surveillance ([@bib2], [@bib17]). One area where there might be an opportunity to augment anti-pathogen responses in the CNS relates to the function of inhibitory receptors. The clinical success of targeting PD-1, PD-L1, and CTLA-4 to reinvigorate pre-existing anti-tumor T cell responses has the potential to determine whether these pathways operate constitutively in the CNS. There is an expanding cancer patient base that are treated with these therapies, but it is not yet clear whether these treatments will impact the immune response to latent infections of the CNS. In one scenario, treatments that target inhibitory pathways might lead to silent clearance of pre-existing chronic infections of the CNS and/or result in overt or transient immune pathology, perhaps associated with pathogen clearance. The latter findings would argue that immunotherapy is a viable approach to target latent of persistent infections of the CNS. The utility of this type of approach is illustrated by the success of CAR T cell therapies to target cancer and which might be applicable to infectious diseases ([@bib177]). The willingness to target CNS infections would need to be based on the belief that T cells are part of the normal surveillance in the brain, and that these populations could be engineered to traffic into the CNS and function there with specificity and minimal bystander damage.
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